{"filing":{"accession_number":"0001213900-26-104177","cik":"0002079272","ticker":"LABT","company_name":"Lakewood-Amedex Biotherapeutics Inc.","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-22","primary_document":"ea0306660-8k_lakewood.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2079272/000121390026104177/ea0306660-8k_lakewood.htm"},"events":[{"id":35529,"run_id":32727,"accession_number":"0001213900-26-104177","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"This Item 5.07 discloses the results of Lakewood-Amedex's 2026 Annual Meeting of Stockholders held on September 22, 2026, including voting outcomes on five proposals: election of four directors, amendment to increase authorized shares from 12.5M to 100M, authorization for a reverse stock split up to 1:20, amendment to the 2020 Equity Incentive Plan to increase shares to 400,000, and ratification of CBIZ CPAs P.C. as independent auditor. All proposals passed with substantial majorities. The authorization for a reverse stock split and increase in authorized shares are particularly material to investors assessing potential dilution and capital structure changes.","company_name":"Lakewood-Amedex Biotherapeutics Inc.","ticker":"LABT","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":[{"id":39604,"accession_number":"0001213900-26-104177","item_number":"5.07","item_title":"Submission of Matters to a Vote","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the results of Lakewood-Amedex's 2026 Annual Meeting of Stockholders held on September 22, 2026, including voting outcomes on five proposals: election of four directors, amendment to increase authorized shares from 12.5M to 100M, authorization for a reverse stock split up to 1:20, amendment to the 2020 Equity Incentive Plan to increase shares to 400,000, and ratification of CBIZ CPAs P.C. as independent auditor. All proposals passed with substantial majorities. The authorization for a reverse stock split and increase in authorized shares are particularly material to investors assessing potential dilution and capital structure changes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T10:01:43.632649+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39604,"accession_number":"0001213900-26-104177","item_number":"5.07","item_title":"Submission of Matters to a Vote","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the results of Lakewood-Amedex's 2026 Annual Meeting of Stockholders held on September 22, 2026, including voting outcomes on five proposals: election of four directors, amendment to increase authorized shares from 12.5M to 100M, authorization for a reverse stock split up to 1:20, amendment to the 2020 Equity Incentive Plan to increase shares to 400,000, and ratification of CBIZ CPAs P.C. as independent auditor. All proposals passed with substantial majorities. The authorization for a reverse stock split and increase in authorized shares are particularly material to investors assessing potential dilution and capital structure changes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T10:01:43.632649+00:00","company_name":"Lakewood-Amedex Biotherapeutics Inc.","ticker":"LABT","filing_date":"2026-09-28"}]}